Lodi, SaraGünthard, Huldrych FGill, JohnPhillips, Andrew NDunn, DavidVu, QuangSiemieniuk, ReedGarcia, FedericoLogan, RogerJose, SophieBucher, Heiner CScherrer, Alexandra UReiss, Petervan Sighem, ArdBoender, T SoniaPorter, KholoudGilson, RichardParaskevis, DimitriosSimeon, MetallidisVourli, GeorgiaMoreno, SantiagoJarrin, InmaculadaSabin, CarolineHernán, Miguel A2023-02-082023-02-082019http://hdl.handle.net/10668/14723For people living with HIV, major guidelines in high-income countries recommend testing for transmitted drug resistance (TDR) to guide the choice of first-line antiretroviral therapy (ART). However, individuals who fail a first-line regimen can now be switched to one of several effective regimens. Therefore, the virological and clinical benefit of TDR testing needs to be evaluated. We included individuals from the HIV-CAUSAL Collaboration who enrolled Of 25,672 eligible individuals (82% males, 52% diagnosed in 2010 or later), 17,189 (67%) were tested for TDR within 3 months of baseline. Of these, 6% had intermediate- or high-level TDR to any antiretroviral drug. The estimated 5-year proportion virologically suppressed was 77% under TDR testing and 74% under no TDR testing; HR 1.06 (95% confidence interval: 1.03 to 1.19). The estimated 5-year risk of AIDS or death was 6% under both strategies; HR 1.03 (95% confidence interval: 0.95 to 1.12). TDR prevalence was low. Although TDR testing improved virological response, we found no evidence that it reduced the incidence of AIDS or death in first 5 years after diagnosis.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/AdultAnti-HIV AgentsAnti-Retroviral AgentsCD4 Lymphocyte CountDrug Resistance, ViralDrug Therapy, CombinationFemaleHIV InfectionsHIV-1HumansMaleMiddle Agedresearch article31609929open access10.1097/QAI.00000000000021351944-7884PMC7830777https://journals.lww.com/jaids/Fulltext/2019/11010/Effectiveness_of_Transmitted_Drug_Resistance.12.aspxhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830777/pdf